9,131 results match your criteria Imaging in Small Cell Lung Cancer


Lesser Known Facts of Small Cell Lung Cancer.

J Comput Assist Tomogr 2019 Feb 11. Epub 2019 Feb 11.

From the University Hospitals-Cleveland Medical Center, Cleveland, OH.

Until recently, the treatment of small cell lung cancer (SCLC), a malignancy classically described as having a robust response to first-line therapy with near-universal recurrence, has remained relatively unchanged. Advancements in the management of SCLC have lagged behind those seen for non-small cell lung cancers. As the era of precision medicine and targeted immunotherapy evolves, radiologists must be familiar with the modern treatment paradigms of SCLC and associated imaging patterns, including classic and nonclassic appearances of treatment complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RCT.0000000000000847DOI Listing
February 2019

Patterns of follow-up care after curative radiotherapy ± chemotherapy for stage I-III non-small cell lung cancer.

Asia Pac J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

South Western Sydney Clinical School, University of NSW, NSW, Australia.

Objectives: To describe patterns of follow-up care for non-small cell lung cancer patients treated with curative radiotherapy and to evaluate the role of routine imaging.

Materials And Methods: We retrospectively analyzed follow-up care of patients with stage I-III non-small cell lung cancer treated with curative radiotherapy (minimum dose of 50 Gy) between 2007 and 2011 at three Sydney institutions. Patient demographics, tumor characteristics and treatment factors were collected from oncology and hospital records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13127DOI Listing
February 2019

Prognostic value of tumor solid-part size and solid-part volume in patients with clinical stage I non-small cell lung cancer.

J Thorac Dis 2018 Dec;10(12):6491-6500

Department of Thoracic Surgery, Tokyo Medical University, Tokyo, Japan.

Background: This study aimed to predict the malignant potential of clinical stage I non-small cell lung cancer (c-I NSCLC) by semiautomatic three-dimensional (3D) volumetric measurement of a tumor (3D-data) and the axial computed tomography (CT) data derived from a 3D volumetric dataset (2D-data). The predictive performance was evaluated in terms of overall survival (OS), disease-free survival (DFS), and pathological invasive factors (positive lymphatic invasion, blood vessel invasion, pleural invasion, or lymph node metastasis).

Methods: We identified 252 patients (122 male; mean age, 68 years; range, 23-84 years) with c-I NSCLC who underwent high resolution CT and reconstruction of 3D imaging, followed by complete resection between January 2012 and December 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.11.08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344704PMC
December 2018

Hyperprogressive disease of non-small-cell lung adenocarcinoma under immune-checkpoint inhibitors: A new response pattern to be recognized by the radiologist.

Diagn Interv Imaging 2019 Feb 7. Epub 2019 Feb 7.

Grenoble Alpes University, 23, avenue Maquis du Grésivaudan, 38700 La Tronche, France; Thoracic Oncology Unit, Department of Pneumology, CHU Grenoble Alpes, 38043 Grenoble cedex 09, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.diii.2018.12.004DOI Listing
February 2019

Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.

Cancer Biol Ther 2019 Feb 11:1-6. Epub 2019 Feb 11.

a Department of Thoracic Surgery , Shenzhen People's Hospital, Second Clinical Medical College of Jinan University.

Patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping can benefit from crizotinib treatment. Currently, the main resistance mechanisms to crizotinib are MET D1228N and Y1230C mutations. We reported a case of a Chinese NSCLC patient with MET exon 14 skipping detected by targeted next-generation sequencing (NGS) achieved clinical and imaging remission after crizotinib treatment. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/15384047.2019.1
Publisher Site
http://dx.doi.org/10.1080/15384047.2019.1566049DOI Listing
February 2019
1 Read

Pathways to diagnosis of non-small cell lung cancer: a descriptive cohort study.

NPJ Prim Care Respir Med 2019 Feb 8;29(1). Epub 2019 Feb 8.

School of Public Health, University of Sydney, Sydney, NSW, Australia.

Little has been published on the diagnostic and referral pathway for lung cancer in Australia. This study set out to quantify general practitioner (GP) and lung specialist attendance and diagnostic imaging in the lead-up to a diagnosis of non-small cell lung cancer (NSCLC) and identify common pathways to diagnosis in New South Wales (NSW), Australia. We used linked health data for participants of the 45 and Up Study (a NSW population-based cohort study) diagnosed with NSCLC between 2006 and 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41533-018-0113-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368611PMC
February 2019
1 Read

Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery.

J Exp Clin Cancer Res 2019 Feb 8;38(1):62. Epub 2019 Feb 8.

Department of Oncology, Zhengzhou Central Hospital, Zhengzhou, Henan, China.

Objective: To investigate the lung cancer-promoting mechanism of mesenchymal stem cell-secreted extracellular vesicles (MSC-EV).

Methods: EV were isolated from culture media of human bone marrow-derived MSCs that were pre-challenged with or without hypoxia (referred to as H-EV and N-EV, respectively). After treatment with N-EV or H-EV, A549 and H23 cell proliferation, apoptosis, trans-well invasion and epithelial-to-mesenchymal transition (EMT) were examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1027-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367822PMC
February 2019
1 Read

Recent Advances in Pathology: The 2019 Annual Review Issue of the Journal of Pathology.

J Pathol 2019 Feb 8. Epub 2019 Feb 8.

RECAMO, Masaryk Memorial Cancer Institute, Brno, Czech Republic.

In this Annual Review Issue of The Journal of Pathology, we present 15 invited reviews on topical aspects of pathology, ranging from the impacts of the microbiome in human disease through mechanisms of cell death and autophagy to recent advances in immunity and the uses of genomics for understanding, classifying and treating human cancers. Each of the reviews is authored by experts in their fields and our intention is to provide comprehensive updates in specific areas of pathology in which there has been considerable recent progress. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/path.5255
Publisher Site
http://dx.doi.org/10.1002/path.5255DOI Listing
February 2019
4 Reads

Repeatability of [F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients.

EJNMMI Res 2019 Feb 7;9(1):14. Epub 2019 Feb 7.

University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.

Background: Total metabolic active tumour volume (TMATV) and total tumour burden (TTB) are increasingly studied as prognostic and predictive factors in non-small cell lung cancer (NSCLC) patients. In this study, we investigated the repeatability of TMATV and TTB as function of uptake interval, positron emission tomography/computed tomography (PET/CT) image reconstruction settings, and lesion delineation method. We used six lesion delineation methods, four direct PET image-derived delineations and two based on a majority vote approach, i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13550-019-0481-1DOI Listing
February 2019
2 Reads

Commentary regarding "Residential radon and small cell lung cancer. A systematic review".

Cancer Lett 2019 Feb 4. Epub 2019 Feb 4.

Medical physics Department, Shiraz University of Medical Sciences, Shiraz, United States; Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, PA, 19111, United States. Electronic address: https://www.foxchase.org/sm-mortazavi.

Rodríguez-Martínez et al. proposed a systematic review of residential radon and small cell lung cancer. Although this is a noteworthy project, it must utilize the complete set of radon data and provide a rigorous analysis of these data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.01.030DOI Listing
February 2019

Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.

Eur J Nucl Med Mol Imaging 2019 Feb 1. Epub 2019 Feb 1.

Department of Radiation Oncology, West German Cancer Center, University of Duisburg-Essen Medical School, Hufelandstr. 55, 45122, Essen, Germany.

Purpose: According to the ACRIN 6668/RTOG 0235 trial, pretreatment metabolic tumour volume (MTV) as detected by F-fluorodeoxyglucose PET/CT is a prognostic factor in patients with stage III non-small-cell lung cancer (NSCLC) after definitive radiochemotherapy (RCT). To validate the prognostic value of MTV in patients with stage III NSCLC after RCT, we analysed mature survival data from the German phase III trial ESPATUE.

Methods: This analysis included patients who were staged by PET/CT and who were enrolled in the ESPATUE trial, a randomized study comparing definitive RCT (arm A) with surgery (arm B) after induction chemotherapy and RCT in patients with resectable stage IIIA/IIIB NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-4270-xDOI Listing
February 2019

[Clinical significance of recombinant virus-specific detection for viable circulating tumor cells in lung cancer patients].

Zhonghua Jie He He Hu Xi Za Zhi 2019 Feb;42(2):101-105

Department of Respiratory and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.

To investigate the clinical significance of recombinant virus-specific detection for detecting viable circulating tumor cell (CTC) in lung cancer patients. From June 2017 to August 2018, 63 lung cancer patients diagnosed by imaging and pathology at the Department of Respiratory and Critical Care Medicine, Beijing Anzhen Hospital were recruited for this study, including 38 cases of adenocarcinoma, 13 squamous cell carcinoma, and 12 small cell carcinoma. The patients consisted of 36 males and 27 females, with an average age of (65±11) years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.1001-0939.2019.02.005DOI Listing
February 2019
1 Read

Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: A case report.

Medicine (Baltimore) 2019 Feb;98(5):e14328

Department of Medical Oncology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Rationale: Lung cancer is the leading cause of cancer-associated deaths all over the world. Although the prognosis of lung cancer has improved over the past decade due to progression in surgical techniques and systematic treatments, the patients with advanced disease still suffer poor survival. There are no standard treatment strategies for patients who have failed to respond to at least 2 lines of chemotherapy in non-small cell lung cancer (NSCLC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014328DOI Listing
February 2019
1 Read

Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.

Cardiovasc Intervent Radiol 2019 Jan 30. Epub 2019 Jan 30.

Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwuweiqi Road, Jinan, 250021, Shandong Province, China.

Background: Most epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors (TKIs) experience oligoprogressive disease. Local ablation for isolated resistant sites continued with the original EGFR-TKI showed good efficacy in these patients. We conducted this multicenter retrospective study to investigate the potential benefit of thermal ablation in NSCLC patients that developed extra-central nervous system (CNS) oligoprogressive disease during TKI treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00270-018-02153-xDOI Listing
January 2019
1 Read

Tissue curvature and apicobasal mechanical tension imbalance instruct cancer morphogenesis.

Nature 2019 Feb 30;566(7742):126-130. Epub 2019 Jan 30.

Adult Stem Cell Laboratory, The Francis Crick Institute, London, UK.

Tubular epithelia are a basic building block of organs and a common site of cancer occurrence. During tumorigenesis, transformed cells overproliferate and epithelial architecture is disrupted. However, the biophysical parameters that underlie the adoption of abnormal tumour tissue shapes are unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-019-0891-2DOI Listing
February 2019

Current and Future Oncology Management in the United States.

J Manag Care Spec Pharm 2019 Feb;25(2):272-281

1 Global Partners, Powell, Ohio.

Background: The cost of treating cancer patients is high and rising in the United States. Payers are exposed to cost through doctor visits, laboratory tests, imaging tests, radiation treatment, drugs, hospital stays, surgery, home care, transportation and travel, and caregiving. This study focuses on the cost of medication from the viewpoint of U. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18553/jmcp.2019.25.2.272DOI Listing
February 2019

M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.

Oncologist 2019 Jan 29. Epub 2019 Jan 29.

Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Background: The 8th edition of TNM staging of non-small cell lung cancer (NSCLC) has revised M classification and defined M1b disease with single extrathoracic metastasis, which is distinguished from M1c with multiple extrathoracic metastases. We investigated the prevalence, characteristics, and overall survival (OS) of M1b disease in patients with stage IV NSCLC.

Methods: The study reviewed the medical records and imaging studies of 567 patients with stage IV NSCLC to determine M stage using the 8th edition of TNM staging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0596DOI Listing
January 2019

[Leptomeningeal metastasis of EGFR (+) lung adenocarcinoma: a case report].

Tuberk Toraks 2018 Dec;66(4):340-344

Division of Chest Diseases, University of Health Sciences, Dr. Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital, Izmir, Turkey.

Leptomeningeal metastasis is a very rare complication of infiltration of leptomeninges and subarachnoid space with malignant cells. It is an indicator of poor prognosis. Its incidence is 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5578/tt.67609DOI Listing
December 2018
4 Reads

Assessing robustness of radiomic features by image perturbation.

Sci Rep 2019 Jan 24;9(1):614. Epub 2019 Jan 24.

OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany.

Image features need to be robust against differences in positioning, acquisition and segmentation to ensure reproducibility. Radiomic models that only include robust features can be used to analyse new images, whereas models with non-robust features may fail to predict the outcome of interest accurately. Test-retest imaging is recommended to assess robustness, but may not be available for the phenotype of interest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-36938-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345842PMC
January 2019
2 Reads

[Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI
- Analysis of 2 Cases].

Zhongguo Fei Ai Za Zhi 2019 Jan;22(1):52-56

Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.

Tyrosine kinase inhibitor (TKI) have been proved to be effective in the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitive mutation, which is superior to chemotherapy. However, there are still some patients with sensitive mutations have primary drug resistance. It may be related to the coexistence of susceptible and resistant mutations of EGFR gene, downstream mutations of EGFR pathway, MET amplification and BIM deletion polymorphism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.01.10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348160PMC
January 2019
3 Reads

Desmoplastic Small Round Cell Tumor: Imaging Pattern of Disease at Presentation.

AJR Am J Roentgenol 2019 Jan 23:W1-W10. Epub 2019 Jan 23.

4 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Objective: The purpose of this study is to evaluate the clinical, pathologic, and multimodality cross-sectional imaging features of a cohort of 94 patients with desmoplastic small round cell tumor (DSRCT).

Materials And Methods: This retrospective study of 94 patients with pathologically verified DSRCT was conducted at a tertiary cancer center between 2001 and 2013. Epidemiologic, clinical, pathologic, and imaging findings were recorded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.18.20179DOI Listing
January 2019

Resected Pure Small Cell Lung Carcinomas and Combined Small Cell Lung Carcinomas: Histopathology Features, Imaging Features, and Prognoses.

AJR Am J Roentgenol 2019 Jan 23:1-9. Epub 2019 Jan 23.

3 Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Objective: The objective of our study was to investigate histopathology features, imaging features, and prognoses of surgically resected pure small cell lung carcinomas (SCLCs) and combined SCLCs.

Materials And Methods: Forty-one patients with a pure SCLC or a combined SCLC underwent preoperative chest CT and F-FDG PET/CT and subsequent surgical resection. The clinicopathologic findings were noted by reviewing the electronic medical records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.18.20519DOI Listing
January 2019
2 Reads

Impact of different image reconstructions on PET quantification in non-small cell lung cancer: a comparison of adenocarcinoma and squamous cell carcinoma.

Br J Radiol 2019 Jan 23:20180792. Epub 2019 Jan 23.

1 Department of Nuclear Medicine, University Hospital Zurich , Zurich , Switzerland.

Objective:: Positron emission tomography (PET) using 18F-fluordeoxyglucose (F-FDG) is an established imaging modality for tumor staging in patients with non-small cell lung cancer (NSCLC). There is a growing interest in using F-FDG PET for therapy response assessment in NSCLC which relies on quantitative PET parameters such as standardized uptake values (SUV). Different reconstruction algorithms in PET may affect SUV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr.20180792DOI Listing
January 2019
1 Read

PET/CT Imaging of NSCLC with a αβ Integrin-Targeting Peptide.

Mol Imaging Biol 2019 Jan 22. Epub 2019 Jan 22.

Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.

Purpose: Targeted therapies are regarded as promising approaches to increase 5-year survival rate of non-small cell lung cancer (NSCLC) patients. Here, we investigated the clinical value of the αβ integrin-specific peptide SFITGv6 as a diagnostic reagent targeting NSCLC.

Methods: Affinity and binding properties of [I]SFITGv6 or [Lu]SFITGv6 for αβ integrin-expressing NSCLC cell lines were evaluated in cell culture experiments including competition, kinetic, internalization, and efflux. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11307-018-1296-6DOI Listing
January 2019
2 Reads

Distribution of metastasis in the brain in relation to the hippocampus: a retrospective single-center analysis of 565 metastases in 116 patients.

Cancer Imaging 2019 Jan 22;19(1). Epub 2019 Jan 22.

Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, China.

Objective: To examine the distribution of brain metastases (BM) in relation to the hippocampus, so as to determine the risk of metastasis in the hippocampus, and thus provide experimental evidence for the hippocampal avoidance (HA) in patients with BM during radiotherapy.

Methods: (1) For the retrospective analysis of 116 patients diagnosed with malignancies, confirmed as BM, from December 2014 to December 2016 at the First Affiliated Hospital of Bengbu Medical College. We obtained the T1-weighted, postcontrast axial, sagittal, and coronal Magnetic Resonance imaging (MRI) images f the patients, in supine position, using the head restraints and head thermoplastic masks to adjust the positioning, with computed tomography (CT) positioning scan ranging from the head to the mandible (layer thickness: 3 mm). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40644-019-0188-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341547PMC
January 2019
1 Read
1.286 Impact Factor

Left systematic mediastinal lymph node dissection.

Multimed Man Cardiothorac Surg 2019 01 2;2019. Epub 2019 Jan 2.

General Surgery Department General Hospital of Athens "Evangelismos'' Athens, Greece.

Sampling, or systematic mediastinal lymph node dissection, is the standard-of-care surgical treatment for early stage non-small cell lung cancer, according to guidelines from the European Society of Thoracic Surgeons. Lymph node status defines disease status and patients' prognosis. In this  video tutorial, a radical ipsilateral mediastinal lymph node dissection in a man suffering from a left, centrally located lung adenocarcinoma is presented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1510/mmcts.2019.001DOI Listing
January 2019

Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis.

BMC Cancer 2019 Jan 21;19(1):95. Epub 2019 Jan 21.

Department of Radiation Oncology, the First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, People's Republic of China.

Background: The efficacy of prophylactic cranial irradiation (PCI) in treating patients with small cell lung cancer (SCLC) has not been clear, and recent randomized studies have demonstrated conflicting results from previously published findings. The purpose of this study was to reevaluate the efficacy of PCI in patients with SCLC and to assess factors associated with its efficacy.

Methods: We conducted a quantitative meta-analysis to explore the efficacy of PCI in patients with SCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-5251-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341615PMC
January 2019

Measurement Variability in Treatment Response Determination for Non-Small Cell Lung Cancer: Improvements Using Radiomics.

J Thorac Imaging 2019 Jan 17. Epub 2019 Jan 17.

Departments of Radiology and Center for Imaging Science.

Multimodality imaging measurements of treatment response are critical for clinical practice, oncology trials, and the evaluation of new treatment modalities. The current standard for determining treatment response in non-small cell lung cancer (NSCLC) is based on tumor size using the RECIST criteria. Molecular targeted agents and immunotherapies often cause morphological change without reduction of tumor size. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RTI.0000000000000390DOI Listing
January 2019
2 Reads

5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas.

J Neurooncol 2019 Feb 18;141(3):595-607. Epub 2019 Jan 18.

Brain Tumor Nanotechnology Laboratory, Department of Neurosurgery, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Introduction: Photodynamic therapy (PDT) is a two-step treatment involving the administration of a photosensitive agent followed by its activation at a specific light wavelength for targeting of tumor cells.

Materials/methods: A comprehensive review of the literature was performed to analyze the indications for PDT, mechanisms of action, use of different photosensitizers, the immunomodulatory effects of PDT, and both preclinical and clinical studies for use in high-grade gliomas (HGGs).

Results: PDT has been approved by the United States Food and Drug Administration (FDA) for the treatment of premalignant and malignant diseases, such as actinic keratoses, Barrett's esophagus, esophageal cancers, and endobronchial non-small cell lung cancers, as well as for the treatment of choroidal neovascularization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-019-03103-4DOI Listing
February 2019
1 Read

Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.

JCO Clin Cancer Inform 2018 12;2:1-12

Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

Purpose: To develop a public-private partnership to study the feasibility of a new approach in collecting and analyzing clinically annotated imaging data from landmark phase III trials in advanced solid tumors.

Patients And Methods: The collection of clinical trials fulfilled the following inclusion criteria: completed randomized trials of > 300 patients, highly measurable solid tumors (non-small-cell lung cancer, colorectal cancer, renal cell cancer, and melanoma), and required sponsor and institutional review board sign-offs. The new approach in analyzing computed tomography scans was to transfer to an academic image analysis laboratory, draw contours semi-automatically by using in-house-developed algorithms integrated into the open source imaging platform Weasis, and perform serial volumetric measurement. Read More

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/CCI.17.00137
Publisher Site
http://dx.doi.org/10.1200/CCI.17.00137DOI Listing
December 2018
6 Reads

Prognostic biological factors of radiation pneumonitis after stereotactic body radiation therapy combined with pulmonary perfusion imaging.

Exp Ther Med 2019 Jan 6;17(1):244-250. Epub 2018 Nov 6.

Department of Radiotherapy, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan 450000, P.R. China.

Radiation pneumonitis (RP) is one of the most common dose-limiting toxicity syndromes in patients with thoracic malignant tumors receiving radiotherapy. The present study aimed to identify biological factors for the prediction of RP. Pulmonary perfusion imaging is capable of reflecting the differential functional activity of various regions of the lung, and in the present study, radiotherapy plans that were established on the basis that pulmonary perfusion images have high biological conformality, which may identify regions vulnerable to RP to spare them from radiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.6936DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307352PMC
January 2019
1 Read

F-FDG and C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study.

EJNMMI Res 2019 Jan 16;9(1). Epub 2019 Jan 16.

Department of Respiratory Medicine, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjyuku-ku, Tokyo, 162-8655, Japan.

Background: 4'-[Methyl-C] thiothymidine (4DST) PET/CT provides DNA synthesis imaging, which represented a higher correlation with the proliferation in advanced non-small cell lung cancer (NSCLC) than that from imaging with FDG. The aim of this prospective study was to evaluate the potential of 4DST in early therapy monitoring for advanced NSCLC, and to compare the results with those from CT and FDG PET/CT.

Results: Patients who had been pathologically diagnosed with advanced NSCLC and were scheduled to receive platinum-doublet chemotherapy (PT-DC) were eligible. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13550-019-0472-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335230PMC
January 2019
1 Read

Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer.

Eur Radiol 2019 Jan 14. Epub 2019 Jan 14.

Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, No. 440, Ji Yan Road, Jinan, 250017, China.

Objectives: To determine the integrative value of clinical, hematological, and computed tomography (CT) radiomic features in survival prediction for locally advanced non-small cell lung cancer (LA-NSCLC) patients.

Methods: Radiomic features and clinical and hematological features of 118 LA-NSCLC cases were firstly extracted and analyzed in this study. Then, stable and prognostic radiomic features were automatically selected using the consensus clustering method with either Cox proportional hazard (CPH) model or random survival forest (RSF) analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-018-5949-2DOI Listing
January 2019
1 Read

[Development of a radiomics signature to predict Ki-67 expression level in non-small cell lung cancer].

Zhong Nan Da Xue Xue Bao Yi Xue Ban 2018 Nov;43(11):1216-1222

Department of Radiology, Third Xiangya Hospital, Central South University, Changsha 410013, China.

Objective: To develop a radiomics signature based on CT image features to estimate the expression level of Ki-67 in non-small cell lung cancer (NSCLC).
 Methods: A total of 108 NSCLC patients, who underwent non-enhanced and contrast-enhanced CT scan in our hospital from January 2014 to November 2017, were retrospectively analyzed. They were confirmed by histopathological examination and undergone Ki-67 expression level test within 2 weeks after CT examination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11817/j.issn.1672-7347.2018.11.008DOI Listing
November 2018
3 Reads

Tumor characteristics of lung cancer in predicting axillary lymph node metastases.

Rev Esp Med Nucl Imagen Mol 2019 Jan 9. Epub 2019 Jan 9.

Trakya University, Faculty of Medicine, Department of Nuclear Medicine, Edirne, Turquía.

Objective: In lung cancer, axillary lymph node metastases (ALM) are rare, and according to the 8th grading system, it is classified as M1b disease. The aim of this study is to evaluate1) the presence of ALM and2) the effect of the primary tumors characteristics on the development of ALM.

Methods: We performed a descriptive cross-sectional study, with retrospective revision, to identify ALM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.remn.2018.09.010DOI Listing
January 2019

Synchronous cerebral arteriovenous malformation and lung adenocarcinoma carcinoma brain metastases: A case study and literature review.

Neurochirurgie 2019 Jan 9. Epub 2019 Jan 9.

Department of Surgery, Division of Neurosurgery, University of Connecticut Health, Farmington, Connecticut, 06032, USA. Electronic address:

Introduction: While there are numerous published cases of arteriovenous malformations (AVMs) developing in the setting of malignancy, it is extremely rare to find them concurrently associated in the brain.

Clinical Case: This is the case of a 55-year-old male who presented to the emergency department complaining of headaches, memory and visual changes. Neuro-imaging revealed a right temporal parietal AVM and an adjoining hyperenhancing occipitotemporal lobe lesion with concern for a possible evolving stroke. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuchi.2018.07.003DOI Listing
January 2019
1 Read

Serum pleiotrophin as a diagnostic and prognostic marker for small cell lung cancer.

J Cell Mol Med 2019 Mar 11;23(3):2077-2082. Epub 2019 Jan 11.

Department of Respiratory Medicine, Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Pleiotrophin (PTN) is involved in tumour progression, angiogenesis and metastasis. The purpose of this study was to investigate the expression level of PTN in the serum of patients with small cell lung cancer (SCLC) and to explore the clinical significance of PTN. Serum samples from 128 patients with SCLC, 120 healthy volunteers (HV) and 60 patients with benign lung disease (BLD) were collected. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jcmm.14116
Publisher Site
http://dx.doi.org/10.1111/jcmm.14116DOI Listing
March 2019
1 Read

Intrathoracic core needle biopsy and repeat biopsy for PD-L1 evaluation in non-small cell lung cancer.

J Thorac Dis 2018 Nov;10(Suppl 33):S4031-S4033

Department of Medical Sciences and Infectious Diseases, Unit of Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

View Article

Download full-text PDF

Source
http://jtd.amegroups.com/article/view/24125/19003
Publisher Site
http://dx.doi.org/10.21037/jtd.2018.09.92DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297461PMC
November 2018
4 Reads

Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro.

Am J Physiol Lung Cell Mol Physiol 2019 Jan 10. Epub 2019 Jan 10.

Department of Respiratory, the First Hospital of Qinhuangdao, China.

The involvement of several microRNAs (miRs) in the initiation and development of tumor through the suppression of the target gene expression has been highlighted. The aberrant expression of microRNA-181d-5p (miR-181d-5p) and cyclin-dependent kinase inhibitor 3 (CDKN3) in non-small-cell lung cancer (NSCLC) was then screened by microarray analysis, In the present study, we performed a series of in vivo and in vitro experiments for the purpose of investigating their role in NSCLC and the underlying mechanism. There was a high expression of CDKN3 while miR-181d-5p was down-regulated in NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajplung.00334.2018DOI Listing
January 2019
5 Reads

Paraneoplastic limbic encephalitis revealing a small cell carcinoma of the lung.

Respir Med Case Rep 2019 27;26:157-160. Epub 2018 Dec 27.

Pulmonology Department, Pavilion 4, Abderrahman Mami Hospital, Tunisia.

Introduction: Paraneoplastic limbic encephalitis is a rare disease, usually associated with small cell lung cancer.

Case Report: We report in this publication the cases with different age brackets, who presented with various neurological symptoms such as repetitive seizures or anterograde amnesia. Cerebral CT-scan, cerebral MRI and anti onco-neural paraneoplastic antibodies were suggesting the diagnosis of paraneoplastic limbic encephalitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmcr.2018.12.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319301PMC
December 2018
2 Reads

In Vivo Calpain Knockdown Using Delivery of siRNA.

Methods Mol Biol 2019 ;1915:219-232

Department of Anesthesiology, University of Illinois College of Medicine, Chicago, IL, USA.

Calpain is an intracellular Ca-dependent non-lysosomal cysteine protease expressed ubiquitously in mammals. In endothelial cells, dysregulation of calpain has been shown to be involved in a wide variety of pathological conditions such as angiogenesis, vascular inflammation, and diabetes. Cell- or tissue-targeted in vivo delivery of small interfering RNA (siRNA) is a powerful research tool in the analysis of protein function and has been proposed as an attractive therapeutic modality that is applicable against a large number of human diseases including cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-8988-1_17DOI Listing
January 2019

Small cell lung cancer presenting with hoarseness.

Postgrad Med J 2019 Jan 5. Epub 2019 Jan 5.

Department of Radiology, Kaohsiung Veterans General Hospital, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/postgradmedj-2018-136217DOI Listing
January 2019
1 Read
1.549 Impact Factor

Synthesis and preliminary evaluation of F-icotinib for EGFR-targeted PET imaging of lung cancer.

Bioorg Med Chem 2019 Feb 28;27(3):545-551. Epub 2018 Dec 28.

Shanghai Institute of Applied Physics (SINAP), Chinese Academy of Sciences, Shanghai 201800, PR China. Electronic address:

Epidermal growth factor receptor (EGFR) has emerged as an attracting target in the field of imaging and treatment for non-small cell lung cancer (NSCLC). Radiolabeled EGFR-tyrosine kinase inhibitors (EGFR-TKIs) specifically targeting EGFR are deemed as promising probes for the imaging of NSCLC. This study aimed to label icotinib (one kind of EGFR-TKI) with F through click reaction to develop a new EGFR-targeting PET probe-F-icotinib. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09680896183188
Publisher Site
http://dx.doi.org/10.1016/j.bmc.2018.12.034DOI Listing
February 2019
1 Read

Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.

Strahlenther Onkol 2019 Jan 4. Epub 2019 Jan 4.

Department of Medical Imaging, National Taiwan University Hospital, National Taiwan University College of Medicine, No.7, Chung-Shan South Road, 100, Taipei, Taiwan.

Purpose: We investigated whether radiologic parameters by dynamic contrast-enhanced (DCE) integrated magnetic resonance-positron-emission tomography (MR-PET) predicts tumor response to treatment and survival in non-metastatic non-small-cell lung cancer (NSCLC) patients receiving chemoradiotherapy (CRT).

Methods: Patients underwent DCE integrated MR-PET imaging 1 week before CRT. The following parameters were analyzed: primary tumor size, gross tumor volume, maximal standardized uptake value (SUV), total lesion glycolysis (TLG), apparent diffusion coefficient (ADC), volume transfer constant (K), reverse reflux rate constant (k), extracellular extravascular volume fraction (v), blood plasma volume fraction (v), and initial area under the time-concentration curve defined over the first 60 s post-enhancement (iAUC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00066-018-1418-8DOI Listing
January 2019
2.914 Impact Factor

Prognostic Value and Clinical Impact of Pretreatment FDG PET in Pulmonary Lymphoepithelioma-Like Carcinoma.

Clin Nucl Med 2019 Feb;44(2):e68-e75

Thoracic Medicine, and.

Purpose: Compared with other forms of non-small cell lung cancer, pulmonary lymphoepithelioma-like carcinoma (LELC) is rarer and portends better outcomes. We sought to investigate the prognostic role and clinical impact of pretreatment F-FDG PET in pulmonary LELC.

Methods: A total of 71 patients with pulmonary LELC were identified through a retrospective review of clinical records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002371DOI Listing
February 2019
2 Reads

Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?

Medicine (Baltimore) 2019 Jan;98(1):e13963

Department of Radiology.

To assess the role of radiomic features in distinguishing squamous and adenocarcinoma subtypes of nonsmall cell lung cancers (NSCLC) and predict EGFR mutations.Institution Review Board-approved study included chest CT scans of 93 consecutive patients (43 men, 50 women, mean age 60 ± 11 years) with biopsy-proven squamous and adenocarcinoma lung cancers greater than 1 cm. All cancers were evaluated for epidermal growth factor receptor (EGFR) mutation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013963DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344142PMC
January 2019
1 Read

Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.

Intern Med 2019 1;58(1):101-104. Epub 2019 Jan 1.

Department of Respiratory Medicine, Matsue Red Cross Hospital, Japan.

A 70-year-old woman was referred to our hospital after a nodular shadow was noted on chest X-ray. Chest computed tomography showed a pulmonary mass in the right upper lobe, and brain magnetic resonance imaging revealed a right-sided frontal lobe tumor. A histological examination of a transbronchial lung biopsy specimen revealed adenocarcinoma with epidermal growth factor receptor mutations involving both exon 19 deletion and exon 20 insertion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.0927-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367085PMC
February 2019
2 Reads

Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients-An external validation.

Eur J Radiol 2019 Jan 28;110:148-155. Epub 2018 Nov 28.

Department of Radiation Oncology (The D-lab), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.

Objective: To validate previously identified associations between radiological features and clinical features with Epidermal Growth Factor Receptor (EGFR)/ Kirsten RAt Sarcoma (KRAS) alterations in an independent group of patients with Non-Small Cell Lung Cancer (NSCLC).

Material And Methods: A total of 122 patients with NSCLC tested for EGFR/KRAS alterations were included. Clinical and radiological features were recorded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2018.11.032DOI Listing
January 2019
2 Reads

[Current Status of Diagnosis and Treatment of Pulmonary Sarcomatoid Carcinoma].

Zhongguo Fei Ai Za Zhi 2018 Dec;21(12):902-906

Department of Thoracic Surgery, Nationanl Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, 
Chinese Academy of Medical Scienses and Peking Union Medical College, Beijing 100021, China.

Pulmonary sarcomatoid carcinoma (PSC) is a rare, poorly differentiated, subtype of non-small cell lung carcinoma (NSCLC) and constitutes approximately 0.1% to 0.5% of all lung malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3779/j.issn.1009-3419.2018.12.07DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318565PMC
December 2018
1 Read

Olaparib nanoparticles potentiated radiosensitization effects on lung cancer.

Int J Nanomedicine 2018 11;13:8461-8472. Epub 2018 Dec 11.

Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China,

Background: Poly (ADP-ribose) polymerase (PARP) is a key enzyme in the repair process of DNA strand breaks (DSBs). Olaparib (Ola) is a PARP inhibitor that is involved in arresting PARP release from radiotherapy (RT)-induced damaged DNA to potentiate the effect of RT. Although the underlying mechanisms for the radiosensitization effects of Ola are well understood in vitro, the radiosensitization effects in vivo are still unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJN.S181546DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294076PMC
February 2019
4 Reads